MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.125.270872

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026

Quantitative PSMA PET Biomarkers for Predicting Response to 177Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.

Kiani Iman, Siri Mohammad Amin, Babaei Mahan, Aliasghari Mohammad Mahdi, Mohammadzadeh Saeed, Mohammadi Sara, Salavati Ali

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

177Lu-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (177Lu-PSMA-617) has emerged as a promising targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). However, response rates to therapy vary among patients. Quantitative PSMA PET biomarkers have been increasingly explored for their prognostic potential in guiding patient selection. This systematic review and meta-analysis aims to evaluate the prognostic value of PSMA PET biomarkers for response to 177Lu-PSMA therapy in patients with mCRPC.

Methods

A systematic search was conducted across PubMed, Scopus, Web of Science, and Embase databases to identify studies evaluating quantitative PSMA PET parameters as predictors of response to 177Lu-PSMA therapy. Hazard ratios (HRs) and 95% CIs for quantitative PSMA PET parameters were extracted and synthesized using random-effects meta-analysis. Heterogeneity was assessed using I 2 statistics, and publication bias was evaluated via funnel plots and the Egger test.

Results

A total of 23 studies met the inclusion criteria. Among PSMA PET parameters, SUVmean, tumor volume (TV), or total lesion (TL) PSMA emerged as significant predictors of overall survival (OS), progression free survival, and prostate-specific antigen response. The pooled HR for SUVmean in predicting OS was 0.93 (95% CI, 0.90-0.96; I 2 = 92.8%), whereas TV showed a HR of 1.37 (95% CI, 1.27-1.47; I 2 = 4.7%), and the TL had a HR of 1.04 (95% CI, 1.03-1.05; I 2 = 16.1%). Additionally, SUVmax and SUVpeak demonstrated limited predictive value.

Conclusion

Our findings indicate that SUVmean, TV, and TL derived from PSMA PET imaging could serve as valuable biomarkers for prognosticating response to 177Lu-PSMA therapy in patients with mCRPC. Future studies should aim to integrate PET biomarkers with clinical and biochemical parameters to improve treatment decision-making.

Для цитирования: Kiani Iman, Siri Mohammad Amin, Babaei Mahan, Aliasghari Mohammad Mahdi, Mohammadzadeh Saeed, Mohammadi Sara, Salavati Ali. Quantitative PSMA PET Biomarkers for Predicting Response to 177Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2026. DOI: 10.2967/jnumed.125.270872.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.